Consequently, cholinesterase inhibitors have become a fundamental approach in AD treatment.526 Targeting both AChE and Butyrylcholinesterase (BuChE) not only alleviates cognitive impairment in AD patients by increasing ACh levels but also serves as a disease-modifying agent, delaying the formation of Aβ plaques.527–529 The dual inhibitor of AChE and BuChE, compound 45, significantly enhanced the learning and memory abilities of aged AD mice. This evidence concerns the gene BCHE and Alzheimer disease.